Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.
about
Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT.Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.Optimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes: A Review of Guide- lines and Recommendations.How we mobilize haemopoietic stem cells.Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.Discordant CD34+ cell results in peripheral blood and hematopoietic progenitor cell-apheresis product: implications for clinical decisions and impact on patient treatment.Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Circulating hematopoietic progenitors and CD34(+) cells predicted successful hematopoietic stem cell harvest in myeloma and lymphoma patients: experiences from a single institution.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devices.Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.An algorithm for utilizing peripheral blood CD34 count as a predictor of the need for plerixafor in autologous stem cell mobilization--cost-effectiveness analysis.Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs.
P2860
Q27692619-5C45B476-3465-4F32-AC1C-C385125F5866Q33411277-268ABA9B-F6D5-4239-9640-A846B0FEA1DFQ35965373-088DE909-A9BD-4E75-B8F5-A7BF93C7A1CBQ36428104-741D3C81-43F0-4A15-A12F-8AE81B0618D1Q36569033-0D440213-F64E-4FDC-AC77-1C421FF4954CQ37682128-DEC4CD0D-2980-4900-9203-3A9753CF7A98Q37914921-FFD697E0-B5A8-4F60-AB52-2B59A03F9DEBQ37943423-CE96E7F6-F859-446C-96DD-97F80256D533Q38117649-7BB3F261-6554-4D69-8BBD-5FA78CA54C9CQ38199707-AE73EA12-FC90-4DBD-8750-14A40AD41BB7Q38200909-26D9A707-0A24-4408-A5A2-B3A4104365FAQ38388461-AD08910C-3460-4D77-A8B5-F735BA3B5A89Q38880504-75922A70-4DFE-4F29-8DAC-B383F68EC5B1Q39303533-C8DC6B97-2B8C-4C62-ACAB-07918516F51FQ44256421-C15CB164-F25C-4CED-8F63-8ABB5EE84CBBQ44607102-059374E2-FA4C-4759-A973-2DA46D9C84EDQ51057684-62B6459C-212A-4415-B818-345491DA8661Q51253946-CD83B170-7926-47CC-9472-52C84672535CQ51385709-DA0A09FC-3144-466C-8246-0273C373CF44Q51776428-1E61FF02-0FE7-4891-81D8-163F36836EF0Q53508311-03993675-1903-46EC-992E-2AB82E4EB8B9
P2860
Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Predicting PBSC harvest failur ...... points for early intervention.
@ast
Predicting PBSC harvest failur ...... points for early intervention.
@en
Predicting PBSC harvest failur ...... points for early intervention.
@nl
type
label
Predicting PBSC harvest failur ...... points for early intervention.
@ast
Predicting PBSC harvest failur ...... points for early intervention.
@en
Predicting PBSC harvest failur ...... points for early intervention.
@nl
prefLabel
Predicting PBSC harvest failur ...... points for early intervention.
@ast
Predicting PBSC harvest failur ...... points for early intervention.
@en
Predicting PBSC harvest failur ...... points for early intervention.
@nl
P2093
P2860
P356
P1476
Predicting PBSC harvest failur ...... points for early intervention
@en
P2093
D Gastineau
I Micallef
P2860
P2888
P304
P356
10.1038/BMT.2010.236
P407
P577
2010-10-11T00:00:00Z
P5875
P6179
1017649654